Am J Gastroenterol. 1987 Jun;82(6):504-6.
Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine. Pharmacologically, famotidine is nine times more potent than ranitidine and 32 times more potent than cimetidine. In the Zollinger-Ellison syndrome famotidine is more potent than cimetidine or ranitidine and has a 30% longer duration of action. Randomized double-blind controlled duodenal ulcer studies reveal famotidine effectively heals active ulcers when compared to placebo and that healing rates are comparable to those seen at 8 wk with ranitidine. Famotidine effectively heals gastric ulcers in 8 wk when compared to placebo. The drug also significantly reduced the recurrence rate of duodenal ulcers in a 6-month controlled trial. Famotidine is a potent H2 antagonist which appears to be safe at high doses, does not cause antiandrogen side effects, and does not interfere with hepatic oxidative metabolism. Further clinical experience will define famotidine's place in the therapeutic armamentarium against peptic ulcer disease.
法莫替丁是一种强效H2受体拮抗剂，含有噻唑环结构，因此在化学上与西咪替丁和雷尼替丁不同。在药理学上，法莫替丁的效力比雷尼替丁强9倍，比西咪替丁强32倍。在卓-艾综合征中，法莫替丁比西咪替丁或雷尼替丁更有效，作用持续时间长30%。随机双盲对照十二指肠溃疡研究表明，与安慰剂相比，法莫替丁能有效治愈活动性溃疡，治愈率与雷尼替丁治疗8周时相当。与安慰剂相比，法莫替丁在8周内可有效治愈胃溃疡。在一项为期6个月的对照试验中，该药物还显著降低了十二指肠溃疡的复发率。法莫替丁是一种强效H2拮抗剂，高剂量时似乎安全，不会引起抗雄激素副作用，也不会干扰肝脏氧化代谢。进一步的临床经验将确定法莫替丁在治疗消化性溃疡疾病的药物库中的地位。
